TREAT-NMD
Company bio:
Neuromuscular diseases (NMDs), such as Duchenne Muscular Dystrophy and Spinal Muscular Atrophy, are rare and complex conditions that require specialist diagnosis, coordinated care, and access to rapidly evolving therapies. However, in many regions, including parts of the Middle East, healthcare professionals have limited access to specialist education, clinical networks, and real-world data needed to support early diagnosis, consistent standards of care, and readiness for emerging treatments such as gene therapies. At the same time, companies developing therapies for rare neuromuscular diseases rely on high-quality patient registries, expert clinical networks, and informed healthcare systems to successfully deliver clinical trials and new treatments to patients. This creates a gap between rapidly advancing therapeutic innovation and the preparedness of healthcare systems and clinicians to diagnose, treat, and support people living with neuromuscular diseases.
For hospitals and healthcare systems in the Middle East, TREAT-NMD provides specialist clinical education, access to international experts, and support in establishing patient registries and data initiatives. These activities help strengthen clinical pathways, support research and clinical trials, and improve outcomes for patients living with neuromuscular diseases.
